Physician profile
Miguel Munoz
NPI 1770629230
$475,799.08
in general payments reported to CMS, 2019-2025
58 companies · $109K in 2025
The $109K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $48K · 2021: $45K · 2022: $84K · 2023: $58K · 2024: $60K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $210K · Travel and Lodging: $7,731 · Food and Beverage: $7,624 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,185 · Education: $80.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $210,323.75 |
| Travel and Lodging | $7,730.97 |
| Food and Beverage | $7,624.07 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,185.00 |
| Education | $80.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $302,888.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $127,926.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $16,592.14 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $7,868.92 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $7,447.44 | 2019-2022 | |
| Dexcom, INC. | $2,596.58 | 2019-2024 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $1,256.92 | 2024-2025 | NP Thyroid 60 |
| Amgen INC. | $991.92 | 2019-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $751.93 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $579.57 | 2019-2025 | Korlym |
| Abbott Laboratories | $571.47 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $441.04 | 2019-2023 | Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.01 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $390.03 | 2021-2025 | |
| Radius Health, INC. | $315.04 | 2019-2025 | Tymlos |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $309.98 | 2019-2023 | Afrezza |
| Abbvie INC. | $278.16 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $274.47 | 2019-2025 | Unithroid |
| Zealand Pharma US, INC. | $268.05 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $262.44 | 2020-2024 | Gvoke Hypopen |
| Cequr Corporation | $260.96 | 2021-2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.42 | 2019-2023 | Cycloset |
| Antares Pharma, INC. | $248.54 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $235.05 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $188.93 | 2021-2025 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $167.85 | 2020-2021 | |
| Companion Medical, INC. | $158.33 | 2019-2020 | |
| Amarin Pharma, INC. | $156.39 | 2019-2022 | |
| Pfizer INC. | $141.03 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $137.42 | 2019 | |
| Shire North American Group INC | $134.45 | 2019 | |
| Eisai INC. | $123.40 | 2019 | |
| Horizon Therapeutics Plc | $97.49 | 2019-2023 | Tepezza |
| Endo Pharmaceuticals INC. | $88.75 | 2019-2021 | |
| Sequel Med Tech, LLC | $83.73 | 2025 | Twiist |
| Becton, Dickinson and Company | $75.69 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $72.79 | 2024-2025 | |
| Beta Bionics, INC. | $67.94 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Kowa Pharmaceuticals America, INC. | $67.39 | 2019-2020 | |
| Vivus LLC | $51.37 | 2019-2021 | |
| Medtronic, INC. | $48.54 | 2021-2023 | Minimed 780g |
| Medtronic Minimed, INC. | $47.53 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $43.08 | 2019-2021 | |
| Nalpropion Pharmaceuticals LLC | $42.44 | 2019 | |
| Ascendis Pharma Endocrinology INC | $41.90 | 2024-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $41.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $38.76 | 2021-2022 | |
| Valeritas, INC. | $37.48 | 2019 | |
| Allergan, INC. | $34.43 | 2019-2020 | |
| Averitas Pharma INC. | $29.72 | 2025 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $29.20 | 2020 | |
| Amryt Pharma Holdings LTD | $25.76 | 2023 | Mycapssa |
| Alfasigma USA, INC. | $19.33 | 2020 | |
| Kerecis Limited | $19.18 | 2019 | |
| Kyowa Kirin, INC. | $18.63 | 2023 | Crysvita |
| Theracosbio, LLC | $18.01 | 2024 | Brenzavvy |
| Almatica Pharma LLC | $17.75 | 2025 | Teriparatide |
| Glaxosmithkline, LLC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.